Jin Ju Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jin Ju Kim has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Saeam Shin
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
9 shared publications - Seung-Tae Lee
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
5 shared publications - Doh Yu Hwang
Division of Hematology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3 shared publications Jong Rak Choi
Department of Laboratory Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea
3 shared publications- Jong Rak Choi
Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea
3 shared publications Hongkyung Kim
Chung Ang Univ, Gwangmyung Hosp, Coll Med, Dept Lab Med, Gwangmyeong, South Korea
2 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Nationwide Survey of Laboratory-Initiated Peripheral Blood Smear Review Practices in Korea: Criteria, Workload, and Reimbursement
Hyunji Kim, M.D., Ph.D., Won Kyung Kwon, M.D., Ph.D., Sooyong Park, M.D., Ph.D., Daehyun Chu, M.D., Jin Jung, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Jong-Mi Lee, M.D., Ph.D., and Myungshin Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0382
- 6 November 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessNationwide Survey of Laboratory-Initiated Peripheral Blood Smear Review Practices in Korea: Criteria, Workload, and Reimbursement
Hyunji Kim, M.D., Ph.D., Won Kyung Kwon, M.D., Ph.D., Sooyong Park, M.D., Ph.D., Daehyun Chu, M.D., Jin Jung, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Jong-Mi Lee, M.D., Ph.D., and Myungshin Kim, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0382
- Open Access
- 19 August 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Baseline Plasma Cell-Free and Circulating Tumor DNA Across Lymphoma Subtypes and Its Prognostic Impact in Diffuse Large B-Cell Lymphoma
Jin Ju Kim, M.D., Yu Ri Kim, M.D., Hongkyung Kim, M.D., Hye Won Kook, M.D., Haerim Chung, M.D., Doh Yu Hwang, M.D., Ji Eun Jang, M.D., June-Won Cheong, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Saeam Shin, M.D. , and Jin Seok Kim, M.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0122
- 19 August 2026
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
Open AccessBaseline Plasma Cell-Free and Circulating Tumor DNA Across Lymphoma Subtypes and Its Prognostic Impact in Diffuse Large B-Cell Lymphoma
Jin Ju Kim, M.D., Yu Ri Kim, M.D., Hongkyung Kim, M.D., Hye Won Kook, M.D., Haerim Chung, M.D., Doh Yu Hwang, M.D., Ji Eun Jang, M.D., June-Won Cheong, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Saeam Shin, M.D. , and Jin Seok Kim, M.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0122
- Open Access
- 1 October 2025
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 15 (4) , 344-348
Coexistent Out-of-frame and In-frame e8a2 BCR::ABL1 Transcripts in a Patient with Chronic Myeloid Leukemia: A Case Report
Jinho Lee, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Jin Ju Kim, M.D., Saeam Shin, M.D.. Lab Med Online 2025;15:344-8. https://doi.org/10.47429/lmo.2025.15.4.344
- 1 October 2025
- Published by Laboratory Medicine Online in Laboratory Medicine Online
- Vol. 15 (4) , 344-348
Open AccessCoexistent Out-of-frame and In-frame e8a2 BCR::ABL1 Transcripts in a Patient with Chronic Myeloid Leukemia: A Case Report
Jinho Lee, M.D., Seung-Tae Lee, M.D., Jong Rak Choi, M.D., Jin Ju Kim, M.D., Saeam Shin, M.D.. Lab Med Online 2025;15:344-8. https://doi.org/10.47429/lmo.2025.15.4.344
- Open Access
- 4 June 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (2) , 475-483
Real‐world clinical experience with NGS‐based chimerism analyses in haematopoietic stem cell transplant patients
Summary: Next‐generation sequencing (NGS) has improved the sensitivity of chimerism assays beyond the limitations of conventional short tandem repeat (STR) methods, enabling the detection of minimal recipient haematopoiesis after haematopoietic stem cell transplantation (HSCT). We evaluated the clinical utility of CASAL, an NGS‐based chimerism assay, in routine practice. We retrospectively analysed 310 patients who underwent STR or CASAL chimerism testing between April 2021 and September 2023. CASAL provided significantly more informative markers than STR (median 18 vs. 6; p < 0.001). Among 260 CASAL samples with paired molecular minimal residual disease (MRD) data, concordance at the 10−4 threshold was ~84%. Low‐level mixed chimerism (2%–5%) detected beyond 1 month post‐HSCT was associated with impending relapse. In survival analyses, patients with both MC and MRD positivity (MC/MRD+) had the highest relapse risk across both platforms. Multivariable Cox regression confirmed MC/MRD+ as an independent predictor of relapse (hazard ratio 5.87, 95% CI: 1.17–29.57). CASAL enables sensitive chimerism monitoring and shows a strong correlation with molecular MRD and clinical outcomes. These findings support its clinical utility for individualized post‐HSCT surveillance, especially in patients lacking leukaemia‐specific molecular targets.
- 4 June 2025
- Published by Wiley in British Journal of Haematology
- Vol. 207 (2) , 475-483
Open AccessReal‐world clinical experience with NGS‐based chimerism analyses in haematopoietic stem cell transplant patients
Summary: Next‐generation sequencing (NGS) has improved the sensitivity of chimerism assays beyond the limitations of conventional short tandem repeat (STR) methods, enabling the detection of minimal recipient haematopoiesis after haematopoietic stem cell transplantation (HSCT). We evaluated the clinical utility of CASAL, an NGS‐based chimerism assay, in routine practice. We retrospectively analysed 310 patients who underwent STR or CASAL chimerism testing between April 2021 and September 2023. CASAL provided significantly more informative markers than STR (median 18 vs. 6; p < 0.001). Among 260 CASAL samples with paired molecular minimal residual disease (MRD) data, concordance at the 10−4 threshold was ~84%. Low‐level mixed chimerism (2%–5%) detected beyond 1 month post‐HSCT was associated with impending relapse. In survival analyses, patients with both MC and MRD positivity (MC/MRD+) had the highest relapse risk across both platforms. Multivariable Cox regression confirmed MC/MRD+ as an independent predictor of relapse (hazard ratio 5.87, 95% CI: 1.17–29.57). CASAL enables sensitive chimerism monitoring and shows a strong correlation with molecular MRD and clinical outcomes. These findings support its clinical utility for individualized post‐HSCT surveillance, especially in patients lacking leukaemia‐specific molecular targets.
- 6 January 2025
- Published by Elsevier in Archives of Medical Research
- Vol. 56 (4) , 103158
Mutational Profiling of Korean Lymphomas and Diffuse Large B-Cell Lymphoma Subtype Classification Using Targeted Panel Sequencing
- 6 January 2025
- Published by Elsevier in Archives of Medical Research
- Vol. 56 (4) , 103158
Mutational Profiling of Korean Lymphomas and Diffuse Large B-Cell Lymphoma Subtype Classification Using Targeted Panel Sequencing
- Open Access
- 30 September 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (1) , 90-95
Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
Seok Jin Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Mi Ri Park, B.S., Bon Park, B.S., Kyung Ju Ryu, Ph.D., Sang Eun Yoon, M.D., Ph.D., Won Seog Kim, M.D., Ph.D., Saeam Shin, M.D., Ph.D., and Seung-Tae Lee, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0257
- 30 September 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 45 (1) , 90-95
Open AccessFeasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma
Seok Jin Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Mi Ri Park, B.S., Bon Park, B.S., Kyung Ju Ryu, Ph.D., Sang Eun Yoon, M.D., Ph.D., Won Seog Kim, M.D., Ph.D., Saeam Shin, M.D., Ph.D., and Seung-Tae Lee, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0257
- Open Access
- 31 July 2024
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 17 (3) , 364-367
The First East Asian Patient With Parkinson’s Disease Caused by the A53E SNCA Mutation With Early Progression to Dementia
The first East Asian Parkinson’s disease caused by A53E SNCA mutation with early progression to dementia
- 31 July 2024
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 17 (3) , 364-367
Open AccessThe First East Asian Patient With Parkinson’s Disease Caused by the A53E SNCA Mutation With Early Progression to Dementia
The first East Asian Parkinson’s disease caused by A53E SNCA mutation with early progression to dementia
- Open Access
- 15 January 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (1) , 314-323
Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes
Purpose We designed and evaluated the clinical performance of a plasma circulating tumor DNA (ctDNA) panel of 112 genes in various subtypes of lymphoma. Materials and Methods Targeted deep sequencing with an error-corrected algorithm was performed in ctDNA from plasma samples that were collected before treatment in 42 lymphoma patients. Blood buffy coat was utilized as a germline control. We evaluated the targeted gene panel using mutation detection concordance on the plasma samples with matched tissue samples analyzed the mutation profiles of the ctDNA. Results Next-generation sequencing analysis using matched tissue samples was available for 18 of the 42 patients. At least one mutation was detected in the majority of matched tissue biopsy samples (88.9%) and plasma samples (83.3%). A considerable number of mutations (40.4%) that were detected in the tissue samples were also found in the matched plasma samples. Majority of patients (21/42) were diffuse large B cell lymphoma patients. The overall detection rate of ctDNA in patients was 85.7% (36/42). The frequently mutated genes included PIM1, TET2, BCL2, KMT2D, KLHL6, HIST1H1E, and IRF8. A cutoff concentration (4,506 pg/mL) of ctDNA provided 88.9% sensitivity and 82.1% specificity to predict ctDNA mutation detection. The ctDNA concentration correlated with elevated lactate dehydrogenase level and the disease stage. Conclusion Our design panel can detect many actionable gene mutations, including those at low frequency. Therefore, liquid biopsy can be applied clinically in the evaluation of lymphoma patients, especially in aggressive lymphoma patients.
- 15 January 2024
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 56 (1) , 314-323
Open AccessCirculating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes
Purpose We designed and evaluated the clinical performance of a plasma circulating tumor DNA (ctDNA) panel of 112 genes in various subtypes of lymphoma. Materials and Methods Targeted deep sequencing with an error-corrected algorithm was performed in ctDNA from plasma samples that were collected before treatment in 42 lymphoma patients. Blood buffy coat was utilized as a germline control. We evaluated the targeted gene panel using mutation detection concordance on the plasma samples with matched tissue samples analyzed the mutation profiles of the ctDNA. Results Next-generation sequencing analysis using matched tissue samples was available for 18 of the 42 patients. At least one mutation was detected in the majority of matched tissue biopsy samples (88.9%) and plasma samples (83.3%). A considerable number of mutations (40.4%) that were detected in the tissue samples were also found in the matched plasma samples. Majority of patients (21/42) were diffuse large B cell lymphoma patients. The overall detection rate of ctDNA in patients was 85.7% (36/42). The frequently mutated genes included PIM1, TET2, BCL2, KMT2D, KLHL6, HIST1H1E, and IRF8. A cutoff concentration (4,506 pg/mL) of ctDNA provided 88.9% sensitivity and 82.1% specificity to predict ctDNA mutation detection. The ctDNA concentration correlated with elevated lactate dehydrogenase level and the disease stage. Conclusion Our design panel can detect many actionable gene mutations, including those at low frequency. Therefore, liquid biopsy can be applied clinically in the evaluation of lymphoma patients, especially in aggressive lymphoma patients.
- Open Access
- 11 January 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (3) , 279-288
Association Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential
Minkwan Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Seung-Tae Lee, M.D., Ph.D., Yeeun Shim, M.S., Hyeonah Lee, Ph.D., SungA Bae, M.D., Ph.D., Nak-Hoon Son, Ph.D., Saeam Shin, M.D., Ph.D., and In Hyun Jung, M.D., Ph.D.. Ann Lab Med 2024;44:279-88. https://doi.org/10.3343/alm.2023.0268
- 11 January 2024
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 44 (3) , 279-288
Open AccessAssociation Between Aortic Valve Sclerosis and Clonal Hematopoiesis of Indeterminate Potential
Minkwan Kim, M.D., Ph.D., Jin Ju Kim, M.D., Ph.D., Seung-Tae Lee, M.D., Ph.D., Yeeun Shim, M.S., Hyeonah Lee, Ph.D., SungA Bae, M.D., Ph.D., Nak-Hoon Son, Ph.D., Saeam Shin, M.D., Ph.D., and In Hyun Jung, M.D., Ph.D.. Ann Lab Med 2024;44:279-88. https://doi.org/10.3343/alm.2023.0268
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Clinical Neurology
- Vol. 20 (2) , 220-222
Mitochondrial-Membrane-Protein-Associated Neurodegeneration in Longitudinal Magnetic Resonance Imaging Over 11 Years of Follow-Up
Lee J, et al. J Clin Neurol. 2024 Mar;20(2):220-222. https://doi.org/10.3988/jcn.2023.0336
- 1 January 2024
- Published by XMLink in Journal of Clinical Neurology
- Vol. 20 (2) , 220-222
Open AccessMitochondrial-Membrane-Protein-Associated Neurodegeneration in Longitudinal Magnetic Resonance Imaging Over 11 Years of Follow-Up
Lee J, et al. J Clin Neurol. 2024 Mar;20(2):220-222. https://doi.org/10.3988/jcn.2023.0336